Date: 2015-03-19
Type of information: Publication of results in a medical journal
phase: preclinical
Announcement: publication of results in the Journal of Translational Medicine
Company: Batu Biologics (USA - CA)
Product: ValloVax™
Action
mechanism: cell therapy/cell immunotherapy/therapeutic vaccine. ValloVax ™is a cellular anti-angiogenic cancer vaccine designed to stimulate an immune response against the tumor endothelium for the initial condition of lung cancer. ValloVax™ targets multiple proteins found on the tumor-associated blood vessels and seeks to target and prevent tumor angiogenesis.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On March 19, 2015, Batu Biologics announced the publication in the Journal of Translational Medicine of the rationale and preclinical data for Batu’s flagship immunotherapeutic product, ValloVax™. ValloVax™ is a therapeutic vaccine that stimulates an immune response against the tumor vasculature for solid tumors. Batu Biologics has recently filed an Investigational New Drug Application (IND designation # 16296) with the FDA seeking clinical approval to initialize a Phase I study for Non-Small Cell Lung Cancer (NSCLC). The publication, which is available at http://www.translational-medicine.com/content/pdf/s12967-015-0441-0.pdf, describes the feasibility and proposed methods of inducing immunity against the tumor endothelium as well as a summary of efficacy and safety studies conducted for the ValloVax™ platform. Immunological targeting of the tumor vasculature remains a desirable approach for cancer therapeutics because of a.) immune accessibility via the blood supply and b.) collateral damage to tumor cells via the activation of coagulation mechanisms. Batu believes that this novel approach to choking tumors of their blood supply will provide the best clinical benefit for late-stage patients with lung cancer. Co-authors and collaborators for the publication include Dr. Amit N. Patel, Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah, Dr. Santosh Kesari, Director of Neuro-Oncology at the UC San Diego Moores Cancer Center, and Dr. Wei-ping Min, Professor, Department of Immunology, University of Western Ontario. Batu Biologics now expects to complete the additional IND-enabling experiments by the end of the second quarter of 2015.
